Full Press Release Details
and REPLACING: Cellectis to Present at the American Society of Gene &
Cell Therapy Annual Meeting
NEW YORK--(BUSINESS WIRE)--April 25, 2017--Regulatory News:
This replaces the announcement made at 22:30 CET April 25, 2017 due to
the following corrections: Under "Oral presentation," the second line
should read: Philippe Duchateau, PhD. Chief Scientific Officer,
Cellectis to Present at the American Society of Gene & Cell Therapy
Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq: CLLS),
a biopharmaceutical company focused on developing immunotherapies based
on gene edited CAR T-cells, today announced that data on its gene-edited
allogeneic off-the-shelf CAR T-cell immunotherapies (UCART) will be
presented at the ASGCT 20th Annual Meeting. The meeting will be held
from May 10th to 13th, 2017 in Washington, D.C., USA.
Development of Gene Edited Allogeneic CAR T-Cell Therapy
Duchateau, PhD. Chief Scientific Officer, Cellectis
Session: 300 - Clinical Advancement of Gene Editing-Moving New Science
to the Clinic - Organized by the Clinical Trials and Regulatory Affairs
Friday, May 12, 2017 from 8:35 AM to 9:10 AM EST
Poster presentations:
176 - Genome-Wide Analysis of TALEN Activity in Primary Cells
Busser, Sonal Temburni, Aymeric Duclert, Philippe Duchateau and Laurent
Session: Gene Targeting and Gene Correction I
Wednesday May 10, 2017
Exhibit Hall A & B South
114 - UCART22: An Allogeneic Adoptive Immunotherapy for Leukemia
Targeting CD22 with CAR T-cells
Anne-Sophie Gautron,
C cile Schiffer-Mannioui, Alan Marechal, Severine Thomas, Agnes Gouble,
Laurent Poirot, Julianne Smith
Session: Cancer-Immunotherapy, Cancer Vaccines I
2017 from 5:30 PM to 7:30pm EST
Exhibit Hall A & B South
372 - Manufacturing of Gene-Modified Mouse CAR T-Cells
Poirot, Brian Busser, Sonal Temburni, Philippe Duchateau
Session: Gene Targeting and Gene Correction II
Thursday May 11, 2017
from 5:15 PM to 7:15 PM EST
Exhibit Hall A & B South
Cellectis is a biopharmaceutical company focused on developing
immunotherapies based on gene-edited CAR T-cells (UCART). The company's
mission is to develop a new generation of cancer therapies based on
engineered T-cells. Cellectis capitalizes on its 17 years of expertise
in genome engineering - based on its flagship TALEN products and
meganucleases as well as its pioneering electroporation PulseAgile
technology - to create a new generation of immunotherapies. CAR
technologies are designed to target surface antigens expressed on cells.
Using its life-science-focused, pioneering genome-engineering
technologies, Cellectis' goal is to create innovative products in
multiple fields and with various target markets.
Cellectis is listed on the Nasdaq market (ticker: CLLS) and on the NYSE
Alternext market (ticker: ALCLS). To find out more about us, visit our
website: www.cellectis.com
Talking about gene editing? We do it. TALEN is a registered trademark
owned by the Cellectis Group
This press release and the information contained herein do not
constitute an offer to sell or subscribe, or a solicitation of an offer
to buy or subscribe, for shares in Cellectis in any country. This press
release contains forward-looking statements that relate to the Company's
objectives based on the current expectations and assumptions of the
Company's management only and involve risk and uncertainties that could
cause the Company to fail to achieve the objectives expressed by the
forward-looking statements above.
For further information, please contact:
Jennifer Moore, 917-580-1088
Caitlin Kasunich, 212-896-1241
Simon Harnest, 646-385-9008
VP of Corporate Strategy